MolMed: Dual business model, incl R&D on proprietary onco and onco-hematology products, and third parties GMP devt and manufacturing services. Owns one of the first authorized cellular therapies (Zalmoxis®, first pt-specific cell therapy for treatment of adult patients affected by leukaemia or other high-risk haematological malignancies) authorized by EMA for all EU Countries, as well as only facility authorized in EU for commercial ex-vivo cell & gene products (Strimvelis and Zalmoxis) manufacturing, serving relevant int'l partners, e.g. GSK, Cellectis, Rocket Pharma et al
Website:
Address:
Via Olgettina, 58
Milano, LM 20132
Italy

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.